Endo names new president, U.S. branded pharmaceuticals
DUBLIN — Endo International this week announced the appointment of Joseph Ciaffoni as president, U.S. branded pharmaceuticals, effective Aug. 15. Ciaffoni was most recently SVP global specialty medicines group for Biogen, where he led development and execution of global strategy for the company’s marketed and pipeline products.
"We are excited to announce the addition of Joe to the Endo executive team. His industry experience is extensive and includes building commercial businesses, leading multi-function organizations and achieving stellar results across primary care, specialty and rare disease markets,” Endo president and CEO Rajiv De Silva said. “His proven track record of success across nearly 20 product launches and the commercialization of more than 70 products will be instrumental as we continue to focus on strategically growing our U.S. Branded business.”
Ciaffoni began at Biogen in 2012, and held various titles there, including SVP U.S. commercial. He has also previously served as EVP and CFO of Shionogi and president of Shionogi Pharmaceuticals, as well as VP sales for Schering-Plough (now Merck).
“I am thrilled to be joining Endo at a time of such significant opportunity for the business,” Ciaffoni said. “I look forward to leading Endo's U.S. branded pharmaceutical business, driving the development and execution of Endo's branded strategy and accelerating key growth drivers while, ultimately, helping improve patients' lives.”
Mediware releases CareTrend for specialty pharmacies
BY DSN STAFF
LENEXA, Kan. — Healthcare software company Mediware Information Systems announced Wednesday that its CareTrend platform is now available for specialty pharmacies. The new platform looks to simplify prescription procession, pharmacy workflow, reimbursement and reporting.
CareTrend allows users to manage their entire workflow operations from a single dashboard that can track output and identify delays while tracking employee productivity in real time. The platform also includes expanded workflow queues that pharmacists can use to increase daily processing through quick-fill options and streamlined order management. CareTrend can also provide customized reporting to meet customer needs.
“We have incorporated customer feedback into our CareTend solution so that today’s specialty pharmacies can thrive using the only complete system designed for this market, “ VP and general manager of Mediware’s home care solutions division, Paul O’Toole, said. “From intake to dispensing to working and reporting, our suite eliminates the need for multiple systems by having everything in one integrated solution.”
Mayne Pharma closes acquisition of Teva, Allergan products
GREENVILLE, N.C. — Mayne Pharma recently announced that it had closed its $652 million acquisition of 42 products from Teva and Allergan. The portfolio includes 37 approved products and five products currently awaiting approval. The acquisition makes Mayne Pharma one of the 25 largest retail generic pharmaceutical companies in the United States and the second-largest generic oral contraceptive provider, the company said.
“We are extremely pleased to complete this transaction that establishes Mayne Pharma as a key player in the U.S. generic market,” president Stefan Cross said. “This portfolio is highly profitable and will significantly extend our size, scale and reach in the United States. Recent investments in people, systems and facilities will readily support the rapidly growing organization and ensure we continue to deliver exceptional service and high-quality products to our customers.”
The company has recently invested in a new manufacturing facility in Greenville, N.C., that will increase its manufacturing capacity by a factor of more than four. It has also grown its workforce by more than 700 employees globally.
The products acquired include the following in different dosage strengths.
- Amethia Lo
- Caziant Tablets
- Clarithromycin Ext Release
- Dextroamphetamine Sulfate ER
- Disopyramide Phosphate
- Methylphenidate ER
- Microgestin 1/20
- Microgestin Fe 1/20
- Microgestin 1.5/30
- Microgestin Fe 1.5/30
- Nortriptyline Hydrochloride
- Tamoxifen Citrate
- Tilia Fe
Loading Post Please Wait...